Related Experiment Video
Updated: Jul 18, 2026
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
Published on: February 14, 2022
Treatment of allograft vasculopathy in heart transplantation
Javier Segovia1, Manuel Gómez-Bueno, Luis Alonso-Pulpón
1Unidad de Trasplante Cardiaco, Hospital Universitario Puerta de Hierro, C/S. Martín de Porres, 4, 28035 Madrid, Spain. jsecu@eresmas.net
Insights
Cardiac allograft vasculopathy is a major concern after heart transplants. Newer immunosuppressants show promise for prophylaxis, while antiproliferative agents may offer future therapeutic benefits.
Area of Science:
- Cardiology
- Immunology
- Transplantation Medicine
Background:
- Cardiac allograft vasculopathy (CAV) is a primary cause of death and illness post-heart transplant.
- Improved prophylactic strategies are reducing CAV's impact.
- Understanding CAV's molecular and cellular basis is key for new diagnostics and treatments.
Purpose of the Study:
- To review current and emerging strategies for managing cardiac allograft vasculopathy.
- To highlight the role of novel immunosuppressive agents in CAV prophylaxis.
- To discuss the potential of antiproliferative agents for established CAV.
Main Methods:
- Review of current literature on cardiac allograft vasculopathy.
- Analysis of the efficacy of newer immunosuppressive agents (sirolimus, everolimus).
- Evaluation of potential therapeutic strategies for established CAV.
Main Results:
- Prophylaxis of early-stage CAV has been successful with agents like sirolimus and everolimus.
- Established CAV often lacks appropriate treatment options like revascularization or retransplantation.
- Antiproliferative agents show potential for symptom relief and improved prognosis.
Conclusions:
- Newer immunosuppressants are likely to be incorporated into future heart transplant protocols for CAV prevention.
- Further clinical trials are necessary to confirm the efficacy of antiproliferative agents in treating established CAV.
Abstract:
Cardiac allograft vasculopathy remains one of the main causes of morbidity and mortality after heart transplantation, although its impact is becoming somewhat smaller as prophylactic measures are implemented. Advances in the understanding of the molecular and cellular mechanisms involved in the genesis and development of cardiac allograft vasculopathy are opening ways for new diagnostic and therapeutic strategies. Successful prophylaxis of the early stages of the disease has been demonstrated with the use of newer immunosuppressive agents, such as sirolimus and everolimus, that will probably be included in future protocols. For most patients with established cardiac allograft vasculopathy, currently available revascularisation methods and retransplantation are not appropriate options. Antiproliferative agents could provide significant improvement in terms of symptom relief and prognosis, but their definite value must be proven in well-designed trials.
